Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure

A. Jayakumar, R. M. Savic, C. K. Everett, D. Benator, D. Alland, C. M. Heilig, Marc H Weiner, S. O. Friedrich, N. A. Martinson, A. Kerrigan, C. Zamudio, S. V. Goldberg, W. C. Whitworth, J. L. Davis, P. Nahid

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (CT) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in CT (P=0.02). The estimated increase in CT slope for every additional 100 μg h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT/week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT, indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.

Original languageEnglish (US)
Pages (from-to)3028-3033
Number of pages6
JournalJournal of Clinical Microbiology
Volume54
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

rifapentine
Mycobacterium tuberculosis
DNA
Tuberculosis
Sputum
Rifampin
Centers for Disease Control and Prevention (U.S.)
Pulmonary Tuberculosis
Routine Diagnostic Tests
Pharmaceutical Preparations
Therapeutics
Body Weight

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Jayakumar, A., Savic, R. M., Everett, C. K., Benator, D., Alland, D., Heilig, C. M., ... Nahid, P. (2016). Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure. Journal of Clinical Microbiology, 54(12), 3028-3033. https://doi.org/10.1128/JCM.01313-16

Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure. / Jayakumar, A.; Savic, R. M.; Everett, C. K.; Benator, D.; Alland, D.; Heilig, C. M.; Weiner, Marc H; Friedrich, S. O.; Martinson, N. A.; Kerrigan, A.; Zamudio, C.; Goldberg, S. V.; Whitworth, W. C.; Davis, J. L.; Nahid, P.

In: Journal of Clinical Microbiology, Vol. 54, No. 12, 01.12.2016, p. 3028-3033.

Research output: Contribution to journalArticle

Jayakumar, A, Savic, RM, Everett, CK, Benator, D, Alland, D, Heilig, CM, Weiner, MH, Friedrich, SO, Martinson, NA, Kerrigan, A, Zamudio, C, Goldberg, SV, Whitworth, WC, Davis, JL & Nahid, P 2016, 'Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure', Journal of Clinical Microbiology, vol. 54, no. 12, pp. 3028-3033. https://doi.org/10.1128/JCM.01313-16
Jayakumar, A. ; Savic, R. M. ; Everett, C. K. ; Benator, D. ; Alland, D. ; Heilig, C. M. ; Weiner, Marc H ; Friedrich, S. O. ; Martinson, N. A. ; Kerrigan, A. ; Zamudio, C. ; Goldberg, S. V. ; Whitworth, W. C. ; Davis, J. L. ; Nahid, P. / Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure. In: Journal of Clinical Microbiology. 2016 ; Vol. 54, No. 12. pp. 3028-3033.
@article{e3585f889f36462da340a6a06737369b,
title = "Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure",
abstract = "The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (CT) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in CT (P=0.02). The estimated increase in CT slope for every additional 100 μg h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT/week (95{\%} confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT, indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.",
author = "A. Jayakumar and Savic, {R. M.} and Everett, {C. K.} and D. Benator and D. Alland and Heilig, {C. M.} and Weiner, {Marc H} and Friedrich, {S. O.} and Martinson, {N. A.} and A. Kerrigan and C. Zamudio and Goldberg, {S. V.} and Whitworth, {W. C.} and Davis, {J. L.} and P. Nahid",
year = "2016",
month = "12",
day = "1",
doi = "10.1128/JCM.01313-16",
language = "English (US)",
volume = "54",
pages = "3028--3033",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure

AU - Jayakumar, A.

AU - Savic, R. M.

AU - Everett, C. K.

AU - Benator, D.

AU - Alland, D.

AU - Heilig, C. M.

AU - Weiner, Marc H

AU - Friedrich, S. O.

AU - Martinson, N. A.

AU - Kerrigan, A.

AU - Zamudio, C.

AU - Goldberg, S. V.

AU - Whitworth, W. C.

AU - Davis, J. L.

AU - Nahid, P.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (CT) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in CT (P=0.02). The estimated increase in CT slope for every additional 100 μg h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT/week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT, indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.

AB - The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (CT) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in CT (P=0.02). The estimated increase in CT slope for every additional 100 μg h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT/week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT, indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.

UR - http://www.scopus.com/inward/record.url?scp=84997771407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997771407&partnerID=8YFLogxK

U2 - 10.1128/JCM.01313-16

DO - 10.1128/JCM.01313-16

M3 - Article

C2 - 27733634

AN - SCOPUS:84997771407

VL - 54

SP - 3028

EP - 3033

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 12

ER -